Mesenchymal stem cells: New insights into bone regenerative applications

Journal of Biomaterials and Tissue Engineering

Volumn 2, Issue 1, 2012, Pages 14-28

  Djouad, Farida ^a,b   Guérit, David ^a,b   Marie, Maumus ^a,b   Toupet, Karine ^a,b   Jorgensen, Christian ^a,b,c   Noël, Danièle ^a,b  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Growth factors; Multipotent stromal cell; Scaffolds; Tissue engineering

Indexed keywords

EID: 84891599775     PISSN: 21579083     EISSN: 21579091     Source Type: Journal    
DOI: 10.1166/jbt.2012.1022     Document Type: Review

References (145)

1. P. Stanka, U. Bellack, and A. Lindner, On the morphology of the terminal microvasculature during endochondral ossification in rats. Bone Miner 13, 93 (1991).
2. J. Bickels, T. Weinstein, D. Robinson, and Z. Nevo, Common skeletal growth retardation disorders resulting from abnormalities within the mesenchymal stem cells reservoirs in the epiphyseal organs pertaining to the long bones. J. Pediatr. Endocrinol. Metab. 23, 1107 (2010).
3. P. Ducy, C. Desbois, B. Boyce, G. Pinero, B. Story, C. Dunstan, E. Smith, J. Bonadio, S. Goldstein, C. Gundberg, A. Bradley, and G. Karsenty, Increased bone formation in osteocalcin-deficient mice. Nature 382, 448 (1996).
4. K. Matsuo and N. Irie, Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 473, 201 (2008).
5. S. R. Goldring and M. B. Goldring, Eating bone or adding it: The Wnt pathway decides. Nat. Med. 13, 133 (2007).
6. C. Zhao, N. Irie, Y. Takada, K. Shimoda, T. Miyamoto, T. Nishiwaki, T. Suda, and K. Matsuo, Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4, 111 (2006).
7. R. Hardy and M. S. Cooper, Bone loss in inflammatory disorders. J. Endocrinol. 201, 309 (2009).
8. K. Kaur, R. Hardy, M. M. Ahasan, M. Eijken, J. P. van Leeuwen, A. Filer, A. M. Thomas, K. Raza, C. D. Buckley, P. M. Stewart, E. H. Rabbitt, M. Hewison, and M. S. Cooper, Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: Implications for inflammation associated bone loss. Ann. Rheum. Dis. 69, 1185 (2010).
9. H. M. Macdonald, K. K. Nishiyama, J. Kang, D. A. Hanley, and S. K. Boyd, Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: A population-based HR-pQCT study. J. Bone Miner Res. 26, 50 (2011).
10. I. E. Bultink, W. F. Lems, P. J. Kostense, B. A. Dijkmans, and A. E. Voskuyl, Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52, 2044 (2005).
11. E. J. Schoon, B. M. Blok, B. J. Geerling, M. G. Russel, R. W. Stockbrugger, and R. J. Brummer, Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 119, 1203 (2000).
12. A. K. Gough, J. Lilley, S. Eyre, R. L. Holder, and P. Emery, Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344, 23 (1994).
13. G. Schett and J. P. David, The multiple faces of autoimmunemediated bone loss. Nat. Rev. Endocrinol. 6, 698 (2010).
14. G. Schett, S. Kiechl, S. Weger, A. Pederiva, A. Mayr, M. Petrangeli, F. Oberhollenzer, R. Lorenzini, K. Redlich, R. Axmann, J. Zwerina, and J. Willeit, High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch. Intern. Med. 166, 2495 (2006).
15. J. Lorenzo, M. Horowitz, and Y. Choi, Osteoimmunology: Interactions of the bone and immune system. Endocr. Rev. 29, 403 (2008).
16. S. R. Goldring and E. M. Gravallese, Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications. Arthritis Res. 2, 33 (2000).
17. K. Polzer, L. Joosten, J. Gasser, J. H. Distler, G. Ruiz, W. Baum, K. Redlich, K. Bobacz, J. S. Smolen, W. van den Berg, G. Schett, and J. Zwerina, Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 69, 284 (2010).
18. E. Romas, N. A. Sims, D. K. Hards, M. Lindsay, J. W. Quinn, P. F. Ryan, C. R. Dunstan, T. J. Martin, and M. T. Gillespie, Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161, 1419 (2002).
19. E. Romas, M. T. Gillespie, and T. J. Martin, Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30, 340 (2002).
20. M. Tsuboi, A. Kawakami, T. Nakashima, N. Matsuoka, S. Urayama, Y. Kawabe, K. Fujiyama, T. Kiriyama, T. Aoyagi, K. Maeda, and K. Eguchi, Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J. Lab. Clin. Med. 134, 222 (1999).
21. K. Okamoto and H. Takayanagi, Osteoclasts in arthritis and Th17 cell development. Int. Immunopharmacol. 11, 543 (2011).
22. J. Sieper, Can structural damage be prevented in ankylosing spondylitis? Curr. Opin. Rheumatol. 21, 335 (2009).
23. D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M. S. Ominsky, D. Dwyer, A. Korb, J. Smolen, M. Hoffmann, C. Scheinecker, D. van der Heide, R. Landewe, D. Lacey, W. G. Richards, and G. Schett, Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156 (2007).
24. N. C. Walsh and E. M. Gravallese, Bone remodeling in rheumatic disease: A question of balance. Immunol. Rev. 233, 301 (2010).
25. X. Feng and J. M. McDonald, Disorders of bone remodeling. Annu. Rev. Pathol. 6, 121 (2011).
26. G. Mazziotti, E. Canalis, and A. Giustina, Drug-induced osteoporosis: Mechanisms and clinical implications. Am. J. Med. 123, 877 (2010).
27. R. J. van't Hof and S. H. Ralston, Nitric oxide and bone. Immunology 103, 255 (2001).
28. R. L. Jilka, Cytokines, bone remodeling, and estrogen deficiency: A 1998 update. Bone 23, 75 (1998).
29. R. Pacifici, Cytokines, estrogen, and postmenopausal osteoporosis-The second decade. Endocrinology 139, 2659 (1998).
30. L. Sun, Y. Peng, A. C. Sharrow, J. Iqbal, Z. Zhang, D. J. Papachristou, S. Zaidi, L. L. Zhu, B. B. Yaroslavskiy, H. Zhou, A. Zallone, M. R. Sairam, T. R. Kumar, W. Bo, J. Braun, L. Cardoso-Landa, M. B. Schaffler, B. S. Moonga, H. C. Blair, and M. Zaidi, FSH directly regulates bone mass. Cell 125, 247 (2006).
31. L. G. Raisz, Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318 (2005).
32. S. Khosla, B. L. Riggs, E. J. Atkinson, A. L. Oberg, L. J. McDaniel, M. Holets, J. M. Peterson, and L. J. Melton, 3rd, Effects of sex and age on bone microstructure at the ultradistal radius: A populationbased noninvasive in vivo assessment. J. Bone Miner Res. 21, 124 (2006).
33. P. R. Ebeling, Clinical practice. Osteoporosis in men. N. Engl. J. Med. 358, 1474 (2008).
34. A. M. Parfitt, Bone remodeling in type I osteoporosis. J. Bone Miner Res. 6, 95 (1991).
35. P. J. Marie, The molecular genetics of bone formation: Implications for therapeutic interventions in bone disorders. Am. J. Pharmacogenomics 1, 175 (2001).
36. I. R. Reid, Glucocorticoid-induced osteoporosis: Assessment and treatment. J. Clin. Densitom. 1, 65 (1998).
37. L. C. Hofbauer, F. Gori, B. L. Riggs, D. L. Lacey, C. R. Dunstan, T. C. Spelsberg, and S. Khosla, Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382 (1999).
38. W. Zhang, N. Yang, and X. M. Shi, Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ). J. Biol. Chem. 283, 4723 (2008).
39. Z. Hamidouche, E. Hay, P. Vaudin, P. Charbord, R. Schule, P. J. Marie, and O. Fromigue, FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. Faseb J. 22, 3813 (2008).
40. J. Shao, X. Xu, G. Li, W. Zhang, J. Qi, J. Wang, M. Cai, L. Cui, L. Zhang, Q. Zhao, and L. Deng, Inhibitory effects of pharmacological doses of dexamethasone on mineralization of mesenchymal progenitor cells in vitro. Pharmazie 64, 674 (2009).
41. S. Takata and N. Yasui, Disuse osteoporosis. J. Med. Invest. 48, 147 (2001).
42. M. S. Cheung and F. H. Glorieux, Osteogenesis Imperfecta: Update on presentation and management. Rev. Endocr. Metab. Disord 9, 153 (2008).
43. M. J. Weiss, D. E. Cole, K. Ray, M. P. Whyte, M. A. Lafferty, R. A. Mulivor, and H. Harris, A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc. Natl. Acad. Sci. USA 85, 7666 (1988).
44. R. Dimitriou, I. M. Carr, R. M. West, A. F. Markham, and P. V. Giannoudis, Genetic predisposition to fracture non-union: A case control study of a preliminary single nucleotide polymorphisms analysis of the BMP pathway. BMC Musculoskelet Disord 12, 44 (2011).
45. R. S. Tare, J. Kanczler, A. Aarvold, A. M. Jones, D. G. Dunlop, and R. O. Oreffo, Skeletal stem cells and bone regeneration: Translational strategies from bench to clinic. Proc. Inst. Mech. Eng. H 224, 1455 (2010).
46. J. F. Keating, P. A. Blachut, P. J. O'Brien, and C. M. Court-Brown, Reamed nailing of Gustilo grade-IIIB tibial fractures. J. Bone Joint Surg. Br. 82, 1113 (2000).
47. D. Marsh, Concepts of fracture union, delayed union, and nonunion. Clin Orthop. Relat. Res. S22 (1998).
48. S. Morshed, L. Corrales, H. Genant, and T. Miclau, 3rd, Outcome assessment in clinical trials of fracture-healing. J. Bone Joint Surg. Am. 90(Suppl 1), 62 (2008).
49. K. A. Hing, Bone repair in the twenty-first century: Biology, chemistry or engineering? Philos Transact A Math. Phys. Eng. Sci. 362, 2821 (2004).
50. A. S. Greenwald, S. D. Boden, V. M. Goldberg, Y. Khan, C. T. Laurencin, and R. N. Rosier, Bone-graft substitutes: Facts, fictions, and applications. J. Bone Joint Surg. Am. 83(Suppl 2), 98 (2001).
51. R. J. Bruno, M. S. Cohen, A. Berzins, and D. R. Sumner, Bone graft harvesting from the distal radius, olecranon, and iliac crest: A quantitative analysis. J. Hand Surg. Am. 26, 135 (2001).
52. G. Stylios, T. Wan, and P. Giannoudis, Present status and future potential of enhancing bone healing using nanotechnology. Injury 38(Suppl 1), S63 (2007).
53. N. C. Keramaris, G. M. Calori, V. S. Nikolaou, E. H. Schemitsch, and P. V. Giannoudis, Fracture vascularity and bone healing: A systematic review of the role of VEGF. Injury 39(Suppl 2), S45 (2008).
54. B. H. Fellah, O. Gauthier, P. Weiss, D. Chappard, and P. Layrolle, Osteogenicity of biphasic calcium phosphate ceramics and bone autograft in a goat model. Biomaterials 29, 1177 (2008).
55. R. A. Carano and E. H. Filvaroff, Angiogenesis and bone repair. Drug Discov. Today 8, 980 (2003).
56. K. R. Garrison, I. Shemilt, S. Donell, J. J. Ryder, M. Mugford, I. Harvey, F. Song, and V. Alt, Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst. Rev. 6, CD006950 (2010).
57. P. J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P. T. Leese, and C. R. Dunstan. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348 (2001).
58. J. G. Emery, P. McDonnell, M. B. Burke, K. C. Deen, S. Lyn, C. Silverman, E. Dul, E. R. Appelbaum, C. Eichman, R. DiPrinzio, R. A. Dodds, I. E. James, M. Rosenberg, J. C. Lee, and P. R. Young, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363 (1998).
59. P. E. Daddona, J. A. Matriano, J. Mandema, and Y. F. Maa, Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm. Res. 28, 159 (2011).
60. E. S. Siris, P. L. Selby, K. G. Saag, F. Borgstrom, R. M. Herings, and S. L. Silverman, Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med. 122, S3 (2009).
61. P. Sambrook and C. Cooper, Osteoporosis. Lancet 367, 2010 (2006).
62. M. Kawai, U. I. Modder, S. Khosla, and C. J. Rosen, Emerging therapeutic opportunities for skeletal restoration. Nat. Rev. Drug Discov. 10, 141 (2011).
63. J. R. Hens, K. M. Wilson, P. Dann, X. Chen, M. C. Horowitz, and J. J. Wysolmerski, TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J. Bone. Miner Res. 20, 1103 (2005).
64. R. L. van Bezooijen, P. ten Dijke, S. E. Papapoulos, and C. W. Lowik, SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16, 319 (2005).
65. D. Padhi, G. Jang, B. Stouch, L. Fang, and E. Posvar, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner Res. 26, 19 (2011).
66. D. J. Heath, A. D. Chantry, C. H. Buckle, L. Coulton, J. D. Shaughnessy, Jr., H. R. Evans, J. A. Snowden, D. R. Stover, K. Vanderkerken, and P. I. Croucher, Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner Res. 24, 425 (2009).
67. M. Fulciniti, P. Tassone, T. Hideshima, S. Vallet, P. Nanjappa, S. A. Ettenberg, Z. Shen, N. Patel, Y. T. Tai, D. Chauhan, C. Mitsiades, R. Prabhala, N. Raje, K. C. Anderson, D. R. Stover, and N. C. Munshi, Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371 (2009).
68. T. D. Rachner, S. Khosla, and L. C. Hofbauer, Osteoporosis: Now and the future. Lancet 377, 1276 (2011).
69. B. Prunet-Marcassus, B. Cousin, D. Caton, M. Andre, L. Penicaud, and L. Casteilla, From heterogeneity to plasticity in adipose tissues: Site-specific differences. Exp. Cell Res. 312, 727 (2006).
70. P. A. Zuk, M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang, H. Mizuno, Z. C. Alfonso, J. K. Fraser, P. Benhaim, and M. H. Hedrick, Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13, 4279 (2002).
71. Y. Fukuchi, H. Nakajima, D. Sugiyama, I. Hirose, T. Kitamura, and K. Tsuji, Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22, 649 (2004).
72. D. Baksh, R. Yao, and R. S. Tuan, Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25, 1384 (2007).
73. Y. A. Romanov, V. A. Svintsitskaya, and V. N. Smirnov, Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord. Stem Cells 21, 105 (2003).
74. S. Gronthos, M. Mankani, J. Brahim, P. G. Robey, and S. Shi, Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc. Natl. Acad. Sci. USA 97, 13625 (2000).
75. Y. Bi, D. Ehirchiou, T. M. Kilts, C. A. Inkson, M. C. Embree, W. Sonoyama, L. Li, A. I. Leet, B. M. Seo, L. Zhang, S. Shi, and M. F. Young, Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat. Med. 13, 1219 (2007).
76. U. Noth, A. M. Osyczka, R. Tuli, N. J. Hickok, K. G. Danielson, and R. S. Tuan, Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. J. Orthop. Res. 20, 1060 (2002).
77. C. De Bari, F. Dell'Accio, P. Tylzanowski, and F. P. Luyten, Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44, 1928 (2001).
78. M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, D. Prockop, and E. Horwitz, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315 (2006).
79. D. J. Prockop, "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol. Ther. 82, 241 (2007).
80. E. M. Horwitz, P. L. Gordon, W. K. Koo, J. C. Marx, M. D. Neel, R. Y. McNall, L. Muul, and T. Hofmann, Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl. Acad. Sci. USA 99, 8932 (2002).
81. Y. Iso, J. L. Spees, C. Serrano, B. Bakondi, R. Pochampally, Y. H. Song, B. E. Sobel, P. Delafontaine, and D. J. Prockop, Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem. Biophys. Res. Commun. 354, 700 (2007).
82. C. M. Cowan, Y. Y. Shi, O. O. Aalami, Y. F. Chou, C. Mari, R. Thomas, N. Quarto, C. H. Contag, B. Wu, and M. T. Longaker, Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat. Biotechnol. 22, 560 (2004).
83. S. Kumar and S. Ponnazhagan, Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. Faseb. J. 21, 3917 (2007).
84. X. S. Zhang, T. A. Linkhart, S. T. Chen, H. Peng, J. E. Wergedal, G. G. Guttierez, M. H. Sheng, K. H. Lau, and D. J. Baylink, Local ex vivo gene therapy with bone marrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice. J. Gene. Med. 6, 4 (2004).
85. M. Maumus, D. Guerit, K. Toupet, C. Jorgensen, and D. Noel, Mesenchymal stem cell-based therapies in regenerative medicine: Applications in rheumatology. Stem Cell Res. Ther. 2, 14 (2011).
86. F. Djouad, C. Bouffi, S. Ghannam, D. Noel, and C. Jorgensen, Mesenchymal stem cells: Innovative therapeutic tools for rheumatic diseases. Nat. Rev. Rheumatol. 5, 392 (2009).
87. M. Krampera, L. Cosmi, R. Angeli, A. Pasini, F. Liotta, A. Andreini, V. Santarlasci, B. Mazzinghi, G. Pizzolo, F. Vinante, P. Romagnani, E. Maggi, S. Romagnani, and F. Annunziato, Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386 (2006).
88. G. Ren, L. Zhang, X. Zhao, G. Xu, Y. Zhang, A. I. Roberts, R. C. Zhao, and Y. Shi, Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141 (2008).
89. G. Y. Rochefort, B. Delorme, A. Lopez, O. Herault, P. Bonnet, P. Charbord, V. Eder, and J. Domenech, Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 24, 2202 (2006).
90. E. A. Horner, J. Kirkham, D. Wood, S. Curran, M. Smith, B. Thomson, and X. B. Yang, Long bone defect models for tissue engineering applications: Criteria for choice. Tissue Eng. Part B Rev. 16, 263 (2010).
91. F. Tortelli, R. Tasso, F. Loiacono, and R. Cancedda, The development of tissue-engineered bone of different origin through endochondral and intramembranous ossification following the implantation of mesenchymal stem cells and osteoblasts in a murine model. Biomaterials 31, 242 (2010).
92. R. Tasso, F. Fais, D. Reverberi, F. Tortelli, and R. Cancedda, The recruitment of two consecutive and different waves of host stem/progenitor cells during the development of tissue-engineered bone in a murine model. Biomaterials 31, 2121 (2010).
93. D. Noel, D. Gazit, C. Bouquet, F. Apparailly, C. Bony, P. Plence, V. Millet, G. Turgeman, M. Perricaudet, J. Sany, and C. Jorgensen, Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells 22, 74 (2004).
94. J. P. Rodriguez, S. Garat, H. Gajardo, A. M. Pino, and G. Seitz, Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J. Cell Biochem. 75, 414 (1999).
95. J. P. Rodriguez, L. Montecinos, S. Rios, P. Reyes, and J. Martinez, Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J. Cell Biochem. 79, 557 (2000).
96. K. B. Jones, T. Seshadri, R. Krantz, A. Keating, and P. C. Ferguson, Cell-based therapies for osteonecrosis of the femoral head. Biol. Blood Marrow Transplant 14, 1081 (2008).
97. I. Bellantuono, A. Aldahmash, and M. Kassem, Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. Biochim. Biophys. Acta 1792, 364 (2009).
98. S. Kuroda, N. Goto, M. Suzuki, K. Kaneda, K. Ohya, H. Shimokawa, and S. Kasugai, Regeneration of bone-and tendon/ligament-like tissues induced by gene transfer of bone morphogenetic protein-12 in a rat bone defect. J. Tissue Eng. 2010, 891049 (2010).
99. F. Cui, X. Wang, X. Liu, A. S. Dighe, G. Balian, and Q. Cui, VEGF and BMP-6 enhance bone formation mediated by cloned mouse osteoprogenitor cells. Growth Factors 28, 306 (2010).
100. K. Song, C. Krause, S. Shi, M. Patterson, R. Suto, L. Grgurevic, S. Vukicevic, M. van Dinther, D. Falb, P. Ten Dijke, and M. H. Alaoui-Ismaili, Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J. Biol. Chem. 285, 12169 (2010).
101. K. Sekiya, M. Nishimura, F. Suehiro, H. Nishimura, T. Hamada, and Y. Kato, Enhancement of osteogenesis by concanavalin A in human bone marrow mesenchymal stem cell cultures. Int. J. Artif. Organs. 31, 708 (2008).
102. D. Chen, M. Zhao, and G. R. Mundy, Bone morphogenetic proteins. Growth Factors 22, 233 (2004).
103. A. H. Reddi, Bone and cartilage differentiation. Curr. Opin. Genet Dev. 4, 737 (1994).
104. S. Kumar, G. Mahendra, T. R. Nagy, and S. Ponnazhagan, Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum. Gene. Ther. 15, 1197 (2004).
105. S. Kumar, T. R. Nagy, and S. Ponnazhagan, Therapeutic potential of genetically modified adult stem cells for osteopenia. Gene Ther. 17, 105 (2010).
106. L. Luca, A. L. Rougemont, B. H. Walpoth, L. Boure, A. Tami, J. M. Anderson, O. Jordan, and R. Gurny, Injectable rhBMP-2-loaded chitosan hydrogel composite: Osteoinduction at ectopic site and in segmental long bone defect. J. Biomed. Mater. Res. A 96, 66 (2011).
107. S. D. Cook, M. W. Wolfe, S. L. Salkeld, and D. C. Rueger, Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J. Bone Joint Surg. Am. 77, 734 (1995).
108. L. Zhu, D. Chuanchang, L. Wei, C. Yilin, and D. Jiasheng, Enhanced healing of goat femur-defect using BMP7 gene-modified BMSCs and load-bearing tissue-engineered bone. J. Orthop. Res. 28, 412 (2010).
109. K. R. Garrison, S. Donell, J. Ryder, I. Shemilt, M. Mugford, I. Harvey, and F. Song, Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: A systematic review. Health Technol. Assess 11, 1 (2007).
110. C. R. Degnin, M. B. Laederich, and W. A. Horton, FGFs in endochondral skeletal development. J. Cell Biochem. 110, 1046 (2010).
111. T. Naganawa, L. Xiao, E. Abogunde, T. Sobue, I. Kalajzic, M. Sabbieti, D. Agas, and M. M. Hurley, In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. Biochem. Biophys. Res. Commun. 339, 490 (2006).
112. D. Qu, J. Li, Y. Li, Y. Gao, Y. Zuo, Y. Hsu, and J. Hu, Angiogenesis and osteogenesis enhanced by bFGF ex vivo gene therapy for bone tissue engineering in reconstruction of calvarial defects. J. Biomed. Mater. Res. A 96, 543 (2011).
113. Y. Wang, C. Wan, L. Deng, X. Liu, X. Cao, S. R. Gilbert, M. L. Bouxsein, M. C. Faugere, R. E. Guldberg, L. C. Gerstenfeld, V. H. Haase, R. S. Johnson, E. Schipani, and T. L. Clemens, The hypoxiainducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 117, 1616 (2007).
114. S. H. Shomento, C. Wan, X. Cao, M. C. Faugere, M. L. Bouxsein, T. L. Clemens, and R. C. Riddle, Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J. Cell Biochem. 109, 196 (2010).
115. L. Liu, Q. Yu, J. Lin, X. Lai, W. Cao, K. Du, Y. Wang, K. Wu, Y. Hu, L. Zhang, H. Xiao, Y. Duan, and H. Huang, Hypoxiainducible factor-1alpha is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev. 20, 1961 (2011).
116. D. Baksh, G. M. Boland, and R. S. Tuan, Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J. Cell Biochem. 101, 1109 (2007).
117. T. Gaur, C. J. Lengner, H. Hovhannisyan, R. A. Bhat, P. V. Bodine, B. S. Komm, A. Javed, A. J. van Wijnen, J. L. Stein, G. S. Stein, and J. B. Lian, Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280, 33132 (2005).
118. T. F. Day, X. Guo, L. Garrett-Beal, and Y. Yang, Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8, 739 (2005).
119. R. Bilkovski, D. M. Schulte, F. Oberhauser, M. Gomolka, M. Udelhoven, M. M. Hettich, B. Roth, A. Heidenreich, C. Gutschow, W. Krone, and M. Laudes, Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J. Biol. Chem. 285, 6170 (2010).
120. Z. L. Deng, K. A. Sharff, N. Tang, W. X. Song, J. Luo, X. Luo, J. Chen, E. Bennett, R. Reid, D. Manning, A. Xue, A. G. Montag, H. H. Luu, R. C. Haydon, and T. C. He, Regulation of osteogenic differentiation during skeletal development. Front Biosci. 13, 2001 (2008).
121. W. K. Kim, V. Meliton, N. Bourquard, T. J. Hahn, and F. Parhami, Hedgehog signaling and osteogenic differentiation in multipotent bone marrow stromal cells are inhibited by oxidative stress. J. Cell Biochem. 111, 1199 (2010).
122. R. M. Pilliar, M. J. Filiaggi, J. D. Wells, M. D. Grynpas, and R. A. Kandel, Porous calcium polyphosphate scaffolds for bone substitute applications-in vitro characterization. Biomaterials 22, 963 (2001).
123. A. El-Ghannam and C. Q. Ning, Effect of bioactive ceramic dissolution on the mechanism of bone mineralization and guided tissue growth in vitro. J. Biomed. Mater. Res. A 76, 386 (2006).
124. N. J. Panetta, D. M. Gupta, N. Quarto, and M. T. Longaker, Mesenchymal cells for skeletal tissue engineering. Panminerva Med 51, 25 (2009).
125. C. T. Laurencin, A. M. Ambrosio, M. D. Borden, and J. A. Cooper, Jr., Tissue engineering: Orthopedic applications. Annu. Rev. Biomed. Eng. 1, 19 (1999).
126. D. P. Link, J. van den Dolder, J. J. van den Beucken, J. G. Wolke, A. G. Mikos, and J. A. Jansen, Bone response and mechanical strength of rabbit femoral defects filled with injectable CaP cements containing TGF-beta 1 loaded gelatin microparticles. Biomaterials 29, 675 (2008).
127. C. D. Friedman, P. D. Costantino, S. Takagi, and L. C. Chow, Bone-Source hydroxyapatite cement: A novel biomaterial for craniofacial skeletal tissue engineering and reconstruction. J. Biomed. Mater. Res. 43, 428 (1998).
128. L. Zhao, M. D. Weir, and H. H. Xu, Human umbilical cord stem cell encapsulation in calcium phosphate scaffolds for bone engineering. Biomaterials 31, 3848 (2010).
129. L. Zhao, M. D. Weir, and H. H. Xu, An injectable calcium phosphate-alginate hydrogel-umbilical cord mesenchymal stem cell paste for bone tissue engineering. Biomaterials 31, 6502 (2010).
130. C. Scotti, B. Tonnarelli, A. Papadimitropoulos, A. Scherberich, S. Schaeren, A. Schauerte, J. Lopez-Rios, R. Zeller, A. Barbero, and I. Martin, Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc. Natl. Acad. Sci. USA 107, 7251 (2010).
131. M. I. Santos and R. L. Reis, Vascularization in bone tissue engineering: Physiology, current strategies, major hurdles and future challenges. Macromol. Biosci. 10, 12 (2010).
132. K. Usami, H. Mizuno, K. Okada, Y. Narita, M. Aoki, T. Kondo, D. Mizuno, J. Mase, H. Nishiguchi, H. Kagami, and M. Ueda, Composite implantation of mesenchymal stem cells with endothelial progenitor cells enhances tissue-engineered bone formation. J. Biomed. Mater. Res. A 90, 730 (2009).
133. J. M. Kanczler and R. O. Oreffo, Osteogenesis and angiogenesis: The potential for engineering bone. Eur. Cell Mater. 15, 100 (2008).
134. H. Yu, P. J. Vandevord, W. Gong, B. Wu, Z. Song, H. W. Matthew, P. H. Wooley, and S. Y. Yang, Promotion of osteogenesis in tissueengineered bone by pre-seeding endothelial progenitor cells-derived endothelial cells. J. Orthop. Res. 26, 1147 (2008).
135. A. H. Undale, J. J. Westendorf, M. J. Yaszemski, and S. Khosla, Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc. 84, 893 (2009).
136. E. M. Horwitz, D. J. Prockop, L. A. Fitzpatrick, W. W. Koo, P. L. Gordon, M. Neel, M. Sussman, P. Orchard, J. C. Marx, R. E. Pyeritz, and M. K. Brenner, Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5, 309 (1999).
137. E. M. Horwitz, D. J. Prockop, P. L. Gordon, W. W. Koo, L. A. Fitzpatrick, M. D. Neel, M. E. McCarville, P. J. Orchard, R. E. Pyeritz, and M. K. Brenner, Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97, 1227 (2001).
138. K. Le Blanc, C. Gotherstrom, O. Ringden, M. Hassan, R. McMahon, E. Horwitz, G. Anneren, O. Axelsson, J. Nunn, U. Ewald, S. Norden-Lindeberg, M. Jansson, A. Dalton, E. Astrom, and M. Westgren, Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 79, 1607 (2005).
139. M. P. Whyte, J. Kurtzberg, W. H. McAlister, S. Mumm, M. N. Podgornik, S. P. Coburn, L. M. Ryan, C. R. Miller, G. S. Gottesman, A. K. Smith, J. Douville, B. Waters-Pick, R. D. Armstrong, and P. L. Martin, Marrow cell transplantation for infantile hypophosphatasia. J. Bone Miner Res. 18, 624 (2003)
140. R. A. Cahill, D. Wenkert, S. A. Perlman, A. Steele, S. P. Coburn, W. H. McAlister, S. Mumm, and M. P. Whyte, Infantile hypophosphatasia: Transplantation therapy trial using bone fragments and cultured osteoblasts. J. Clin Endocrinol. Metab 92, 2923 (2007).
141. R. A. Cahill, O. Y. Jones, M. Klemperer, A. Steele, T. O. Mueller, N. el-Badri, Y. Chang, and R. A. Good, Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells. Biol. Blood Marrow Transplant 10, 709 (2004).
142. M. Tadokoro, R. Kanai, T. Taketani, Y. Uchio, S. Yamaguchi, and H. Ohgushi, New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. J. Pediatr 154, 924 (2009).
143. Y. Katsube, N. Kotobuki, M. Tadokoro, R. Kanai, T. Taketani, S. Yamaguchi, and H. Ohgushi, Restoration of cellular function of mesenchymal stem cells from a hypophosphatasia patient. Gene Ther. 17, 494 (2010).
144. J. W. Zhao, Z. L. Gao, H. Mei, Y. L. Li, and Y. Wang, Differentiation of human mesenchymal stem cells: The potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation. Am. J. Med. Sci. 341, 460 (2011).
145. K. Takada, M. Inaba, N. Ichioka, Y. Ueda, M. Taira, S. Baba, T. Mizokami, X. Wang, H. Hisha, H. Iida, and S. Ikehara, Treatment of senile osteoporosis in SAMP6 mice by intra-bone marrow injection of allogeneic bone marrow cells. Stem Cells 24, 399 (2006).